Metraipolis › archive › dc_4719237c8fd0

Cadonilimab (PD-1/CTLA-4 bispecific antibody) combination therapy for driver gene-negative advanced NSCLC: a single-center retrospective real-world study — Europe PMC PMID:41777658

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41777658
DOI
10.3389/fonc.2026.1718151
License (as archived)
solo-consultazione
Archived
2026-11-05T19:03:09.575Z
SHA-256 of the archived text
04c8e9450dbb04fef39f2dfa013da065a73de3235cbaa6a9a33449166f435297
Stable URL of this page
https://metraipolis.com/documento/dc_4719237c8fd0

How to cite

Cadonilimab (PD-1/CTLA-4 bispecific antibody) combination therapy for driver gene-negative advanced NSCLC: a single-center retrospective real-world study — Europe PMC PMID:41777658 — Europe PMC (en), https://europepmc.org/article/MED/41777658 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_4719237c8fd0 (Metraipolis archive dc_4719237c8fd0, sha256 04c8e9450dbb04fef39f2dfa013da065a73de3235cbaa6a9a33449166f435297)
BibTeX
@misc{dc4719237c8fd0,
  title = {Cadonilimab (PD-1/CTLA-4 bispecific antibody) combination therapy for driver gene-negative advanced NSCLC: a single-center retrospective real-world study — Europe PMC PMID:41777658},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41777658},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_4719237c8fd0; sha256 04c8e9450dbb04fef39f2dfa013da065a73de3235cbaa6a9a33449166f435297},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41777658. Agents can read the archived copy with the MCP tool read_document.